Efficacy and safety of VNS therapy or continued medication management for treatment of adults with drug-resistant epilepsy: systematic review and meta-analysis

Sarah Batson
Rohit Shankar Peninsula Medical School
Joan Conry
Jane Boggs
Rodney Radtke
et al. See next page for additional authors

Let us know how access to this document benefits you

General rights
All content in PEARL is protected by copyright law. Author manuscripts are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.

Take down policy
If you believe that this document breaches copyright please contact the library providing details, and we will remove access to the work immediately and investigate your claim.
Follow this and additional works at: https://pearl.plymouth.ac.uk/pms-research

Recommended Citation
Batson, S., Shankar, R., Conry, J., Boggs, J., Radtke, R., Mitchell, S., Barion, F., Murphy, J., & Danielson, V. (2022) 'Efficacy and safety of VNS therapy or continued medication management for treatment of adults with drug-resistant epilepsy: systematic review and meta-analysis', Journal of Neurology, 269(6).
Available at: https://doi.org/10.1007/s00415-022-10967-6

This Article is brought to you for free and open access by the Faculty of Health at PEARL. It has been accepted for inclusion in Peninsula Medical School by an authorized administrator of PEARL. For more information, please contact openresearch@plymouth.ac.uk.
Authors
Sarah Batson, Rohit Shankar, Joan Conry, Jane Boggs, Rodney Radtke, Stephen Mitchell, Francesca Barion, Joanna Murphy, and Vanessa Danielson
Efficacy and safety of VNS therapy or continued medication management for treatment of adults with drug-resistant epilepsy: systematic review and meta-analysis

Batson, Sarah; Shankar, Rohit; Conry, Joan; Boggs, Jane; Radtke, Rodney; Mitchell, Stephen; Barion, Francesca; Murphy, Joanna; Danielson, Vanessa

Published in:
Journal of Neurology

DOI:
10.1007/s00415-022-10967-6

Publication date:
2022

Document version:
Publisher's PDF, also known as Version of record

Link:
Link to publication in PEARL

Citation for published version (APA):
Batson, S., Shankar, R., Conry, J., Boggs, J., Radtke, R., Mitchell, S., Barion, F., Murphy, J., & Danielson, V. (2022). Efficacy and safety of VNS therapy or continued medication management for treatment of adults with drug-resistant epilepsy: systematic review and meta-analysis. Journal of Neurology, 269(6), 2874-2891. https://doi.org/10.1007/s00415-022-10967-6
Efficacy and safety of VNS therapy or continued medication management for treatment of adults with drug-resistant epilepsy: systematic review and meta-analysis

Sarah Batson1 · Rohit Shankar2 · Joan Conry3 · Jane Boggs4 · Rodney Radtke5 · Stephen Mitchell1 · Francesca Barion6 · Joanna Murphy6 · Vanessa Danielson7

Abstract
Vagus nerve stimulation (VNS) Therapy® is an adjunctive neurostimulation treatment for people with drug-resistant epilepsy (DRE) who are unwilling to undergo resective surgery, have had unsuccessful surgery or are unsuitable for surgery. A systematic review and meta-analysis were conducted to determine the treatment effects of VNS Therapy as an adjunct to anti-seizure medications (ASMs) for the management of adults with DRE. A literature search was performed in August 2020 of the Medline®, Medline® Epub Ahead of Print, Embase, and the Cochrane library databases. Outcomes examined included reduction in seizure frequency, seizure freedom, ASM load, discontinuations, and serious adverse events (SAEs). Comparators included best medical practice, ASMs, low-stimulation or sham VNS Therapy. Four RCTs and six comparative observational studies were identified for inclusion. Against comparators, individuals treated with VNS had a significantly better odds of experiencing a ≥ 50% reduction in seizure frequency (OR: 2.27 [95% CI 1.47, 3.51]; p = 0.0002), a ≥ 75% reduction in seizure frequency (OR: 3.56 [95% CI 1.59, 7.98]; p = 0.002) and a reduced risk for increased ASM load (risk ratio: 0.36 [95% CI 0.21, 0.62]; p = 0.0002). There was no difference in the odds of discontinuation or the rate of SAEs between VNS versus comparators. This meta-analysis demonstrated the benefits of VNS Therapy in people with DRE, which included improvement in seizure frequency without an increase in the rate of SAEs or discontinuations, thereby supporting the consideration of VNS Therapy for people who are not responding to ASMs and those unsuitable or unwilling to undergo surgery.

Keywords Anti-seizure medication · VNS therapy · Meta-analysis · Drug-resistant epilepsy · Seizure frequency

Introduction
Epilepsy is a common neurological condition, affecting approximately 50 million people globally [1]. At least 30% exhibit drug-resistant epilepsy (DRE) and continue to suffer seizures despite treatment [2]. DRE is defined by the International League Against Epilepsy (ILAE) as failure of adequate trials of two tolerated, appropriately chosen and used anti-seizure medication (ASM) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom [3].

People with DRE experience significantly more comorbidities, including depression, seizure-related injuries, and neurological deficits than those without epilepsy or with epilepsy that responds to treatment [4, 5], and have significantly higher mortality risk [6, 7]. DRE is also associated with sudden unexplained death in epilepsy (SUDEP) which represents a major cause of death in this population [8–10].

Sarah Batson
sarah.batson@mtechaccess.co.uk
1 Sarah Batson, Mtech Access Limited, 30 Murdock Road, Bicester OX26 4PP, Oxfordshire, England
2 Neuropsychiatry, Peninsula School of Medicine, University of Plymouth, Plymouth, England
3 Children’s National, Washington, District of Columbia, USA
4 Wake Forest Baptist Health, Winston-Salem, NC, USA
5 Duke University School of Medicine, Durham, NC, USA
6 Pricing, Health Economics, Market Access and Reimbursement (PHEMAR), LivaNova, London, England
7 Global VP, PHEMAR, LivaNova, London, England
People with DRE have substantially higher healthcare costs than those who are seizure-free, including costs associated with medical investigations, treatment costs, emergency room visits, hospitalisations, and outpatient care [18–20]. In addition, people with DRE frequently report feeling stigmatised because of their epilepsy [11].

It has been reported that greater than 30% of people with DRE remain uncontrolled despite the availability of new ASMs, and this statistic has not changed over the last 20 years. [12, 13]. For people who fail to experience sufficient seizure reduction with pharmacologic therapy, alternative approaches include epilepsy brain surgery [14], diet modification [15], and neurostimulation devices [16–19], including Vagus Nerve Stimulation Therapy® (VNS Therapy®) [20, 21].

While for many people with DRE brain surgery can be curative and result in seizure freedom, with up to 52% of people remaining seizure-free (apart from simple partial seizures) 5 years post-intervention [22, 23]. However, not all individuals are suitable candidates, and uptake of surgery is limited by hesitancy, in part due to fears of postoperative permanent neurological deficits [24].

VNS Therapy represents a commonly used neurostimulation option for people with DRE who do not wish to undergo cranial surgery or laser interstitial thermal ablation, who have had unsuccessful surgery or are not suitable for surgery (including individuals with intellectual impairment who may be unable to understand and consent to a non-reversible procedure) [25–27]. VNS is a minimally invasive extracranial device which delivers mild, intermittent electrical pulses to the vagus nerve which then stimulates areas in the brain responsible for seizures [28, 29]. This results in a reduction in seizure frequency [20, 21]. VNS Therapy® has been in clinical use in Europe since 1994 [30] and in the USA since 1997 [31].

This systematic literature review (SLR) and meta-analysis examined the treatment effects of VNS Therapy at up to 2 years as an adjunct to ASMs for the management of adults with DRE based on the most up-to-date evidence from randomised controlled trials (RCTs) and comparative observational studies.

Materials and methods

SLR

An SLR was conducted on the 25th of August 2020 (in alignment with the Preferred Reporting Items for Systematic reviews and Meta-Analyses [PRISMA] checklist) [32] to identify relevant clinical studies (RCTs and observational comparative studies) comparing VNS Therapy as an adjunct to ASMs with relevant comparator arms in adults with DRE followed by a meta-analysis to determine treatment effects for several efficacy and safety outcomes.

The SLR searched the electronic databases of Medline®, Medline® Epub Ahead of Print (In-Process & Other Non-Indexed Citations), Embase, and the Cochrane library to identify relevant clinical studies (RCTs, controlled clinical studies, and prospective registries) examining VNS Therapy and other interventions of interest for the management of patients with DRE. Additional searches of congress proceedings from the past 3 years (American Epilepsy Society [AES], Congress of Neurological Surgeons [CNS] Annual Meeting, European Congress on Epileptology [ECE], International Epilepsy Congress [IEC], International Neuromodulation Society [INS] Congress), reference lists of included publications, and Health Technology Assessment (HTA) bodies were conducted to identify relevant evidence. Search terms are listed in the Supplementary Materials. Citations were screened by a single analyst and independently checked by a second analyst; any discrepancies were resolved by consensus. Outcome data were extracted to a Microsoft® Excel spreadsheet.

For this analysis, the eligibility criteria included comparative clinical studies of VNS Therapy for the management of DRE conducted predominantly in an adult population (i.e., >50% of individuals were aged ≥ 18 years). Eligible comparators to VNS Therapy were: (1) best medical practice (BMP), (2) continuation of stable ASM regimen, (3) addition of ASM, and (4) low-stimulation VNS Therapy (parameters defined in Table 3).

Data collection and risk of bias assessment

General patient/participant demographics were extracted, such as age at time of implant, sex, type of seizure and baseline seizure frequency. Outcomes of interest included reduction in seizure frequency, seizure freedom, ASM load, discontinuations, and serious adverse events (SAEs).

Quality (risk of bias) assessment of RCTs was conducted using the seven-criteria checklist provided in Sect. 2.5 of the National Institute for Health and Care Excellence (NICE) single technology appraisal (STA) user guide for RCTs [33]. Observational studies were assessed using the quality assessment tool for quantitative studies of the Effective Public Health Practice Project (EPHPP) [34].

Meta-analysis

Evidence synthesis was conducted via pairwise meta-analyses based on RCT and comparative observational studies. While observational comparative evidence is of lower quality compared with RCTs due to the inherent bias within such studies, their inclusion was deemed appropriate as observational comparative studies provide longer follow-up.
compared with RCTs. Pairwise meta-analyses were conducted for the outcomes of interest previously described. For one RCT (PuLsE) [35], which reported outcomes up to 2-year post-surgery, the outcome results were restricted to the 12-month timepoint. The 12-month results were included in the meta-analysis. Outcomes for this study were restricted to 12 months to facilitate data comparisons as all other RCTs included in the meta-analysis had shorter followups (range: 3.5–6 months).

**Statistical analysis**

Evidence synthesis was conducted via pairwise meta-analyses based on RCT and comparative observational studies where available. The pairwise meta-analyses were conducted in RevMan 5.3. Heterogeneity was assessed using the chi-squared and I-squared statistics. Results were presented as an odds ratio (OR) or weighted mean difference with 95% confidence intervals (CIs).

**Results**

**SLR**

**RCTs and comparative observational studies**

A total of 48 publications (on 30 unique studies, see Supplementary Materials Table 1) were identified for potential inclusion. In total, 38 VNS Therapy studies did not meet eligibility criteria for inclusion in this meta-analysis (due to publications including non-relevant comparators, no outcomes of interest or publications were superseded by a linked publication); 10 studies were identified for inclusion (four RCT studies [4 unique publications] and six comparative observational studies [5 unique publications]) (Fig. 1). The publication dates ranged between 1993 and 2015.

Four primary study publications from four RCTs in an adult population were included in the analysis; 13 publications linked to these RCTs were excluded as they did not report outcomes of interest or were superseded by the primary study publication [36–47]. A single RCT study (with two linked publications; see Supplementary Materials Table 1) was excluded due to unclear reporting of the enrolled population (i.e., proportion of adults) [48, 49]. A total of 12 adult comparative observational study publications were excluded for the following reasons: no comparator (n=4) [50–53], population of interest (n=2) [54, 55], reported no outcomes of interest (n=5)[56–60] and superseded by a linked primary publication (n=1)[61].

**Study and participant characteristics**

Study design and baseline participant characteristics of the VNS Therapy studies are shown in Tables 1 and 2. The study duration ranged from 3 to 4.5 months for the majority of RCTs [20, 21, 62], with one RCT study lasting 24 months [35]. The study duration for comparative observational studies was typically >12 months (range: 3–32 months) [63–68]. Where reported, the mean participant age ranged 32–41 years for the RCT studies [20, 21, 35, 62] and 25–40 years for comparative observational studies. Disease duration was only reported by half of the studies included (n=5), with the mean duration ranging between 20 and 23 years for RCT studies [20, 21] and 17–26 years for comparative observational studies [63, 66, 68]. Mean seizure frequency ranged from 0.6–1.7 and 0.1–3.5 seizures per day for RCT and non-comparative observational studies, respectively. The mean number of drugs used ranged between 2 and 3 for both RCT [20, 21, 35] and comparative observational studies [64–66, 68]. Three studies compared a low-stimulation setting (control arm) plus background ASMs with a high-stimulation setting; the difference between the low- and high-stimulation parameters is provided in Table 3. Rationale for using the low-stimulation included the facilitation of titration, ethical reasons, inclusion of an active control group and to permit a double-blind trial design [20, 62, 69]. The majority of studies (n=7) compared VNS Therapy with a continuation of the participants’ current ASM regimen; only one comparative observational study reported the type of ASMs participants were taking [65]. None of the included studies made a specific comparison between VNS Therapy and the latest generation of ASMs (e.g., those licensed in the last two decades [i.e., lacosamide, cannabidiol, brivaracetam, perampanel etc.]). VNS is an option for people with DRE who are unsuitable for epilepsy surgery, have had unsuccessful surgery or are unwilling to undergo resective surgery. Only three out of ten of the included studies provided rationale for the use of VNS, reasons included unsuitability for surgery and patient choice [63, 64, 66].

**Participants experiencing ≥ 50% reduction in seizure frequency**

A total of six studies (three RCTs and three comparative observational studies) were included in the analysis. Overall, the pooled odds ratio (based on the results of RCTs and comparative observational studies) for experiencing ≥50% reduction in seizure frequency was statistically significantly greater in adult participants undergoing VNS Therapy compared with low stim VNS Therapy/BMP/ASM (OR: 2.27
Table 1 Summary of included RCTs

| Author/Publication | Location | Treatment length | Duration of follow-up | Comparators | Sample size, n | Age at implant mean (SD [range]) | Sex, F (n [%]) | Mean duration of disease, years | Mean no. of ASMs used at baseline | Seizure types,† | Seizure frequency | Outcomes assessed               |
|--------------------|----------|------------------|-----------------------|-------------|----------------|-----------------------------------|---------------|---------------------------------|----------------------------------|----------------|-----------------|-----------------------------|
| Ryvlin [35] (PuLsE)§ | Canada, Europe | 2 years | 2 years | VNS + BMP | 54 | 38 ± 13 | 24 (50) | NR | 3.5 (SD: ± 1.17) | Structural/metabolic: 26 (54) Unknown: 22 (46) | Median: 5 per week (range: 1 to 123) | Seizure frequency (including ≥ 50%) | HRQoL, ASM usage, Adverse events |
|                      |           |                  |                       | BMP (ASM)   | 58 | 41 ± 11 | 21 (44) |               | 3.2 (SD: ± 1.22) | Structural/metabolic: 26 (54) Unknown: 22 (46) | Median: 4 per week (range: 1 to 42) |                       |                              |
| E-05 (Handforth [20])§ | US | 3 months | 3.5–4 months | VNS high stim | 95 | 32.1 (10.8 [13–54]) | 46 (48.4) | 23 | 2.2 (SD: ± 0.7) | CPS or partially generalised, ± other seizure types | Mean: 1.59 per day (SD ± 1.96) | Median: 0.58 per day | Seizure frequency (including ≥ 50%, ≥ 75% and seizure free) | ASM usage, Quality of life, Adverse events, Discontinuations |
|                      |           |                  |                       | VNS low stim | 103 | 34.2 (10.1 [15–60]) | 59 (57.3) |               | 2.1 (SD: ± 0.7) | Structural/metabolic: 26 (54) Unknown: 22 (46) | Median: 0.97 per day (SD ± 0.94) | Median: 0.51 per day |                              |
| E-03 (Salinsky [21]) § | Europe, North America | 3 months | 3.5–4 months | VNS high stim | 54 | 33.1 (NR) | 21 (39) | 23.1 | 2.09 | SPS: 24 (44.4%) CPS: 50 (92.6%) Partial secondarily generalised: 38 (70.4%) | Mean 1.49 per day (SD: NR) | Median: 0.73 per day | Seizure frequency (including ≥ 50%, ≥ 75% and seizure free) | Adverse events |
|                      |           |                  |                       | VNS low stim | 60 | 33.5 (NR) | 22 (37) | 20.0 | 2.08 | SPS: 25 (41.6%) CPS: 58 (96.6%) Partial secondarily generalised: 33 (55.0%) | Mean 1.71 per day (SD: NR) | Median: 0.82 per day |                              |
| Landy [62] | US | 3–4.5 months | 6.5 months | VNS high stim | 5 | NR | NR | NR | NR | NR | NR | NR | Seizure frequency | Adverse events |

Abbreviations: ASM anti-seizure medication, BMP best medical practice, CPS complex partial seizures, HRQoL health-related quality of life, NR not reported, RCT randomised controlled trial, SD standard deviation, SPS simple partial seizures, VNS vagus nerve stimulation

†May be counted in more than one type; ‡Where applicable; §Cyberonics-sponsored VNS study (Cyberonics is owned by LivaNova)
| Author / Publication | Location | Treatment length | Comparators | Duration of Follow-up | Sample size, n | Age at implant mean (SD [range]) | Sex, F (n [%]) | Mean duration of disease | Mean no. of ASMs used | Seizure types,† n (%‡) | Seizure frequency | Outcomes Assessed |
|----------------------|----------|------------------|-------------|-----------------------|----------------|---------------------------------|---------------|------------------------|---------------------|---------------------|-----------------|-------------------|
| Gonen [64] (Comparative retrospective observational study) | Israel | ≥ 1 year | VNS + ASM | 5.67 years | 33 | > 18 years of age | 14 (42.4) | NR | 2.91 (SD: ± 0.95) | NR | Mean: 3.52 per day (SD 0.67) | Seizure frequency, ASM usage |
| | | | ASM | 4.04 years | 47 | 26 (55.3) | 2.32 (SD: ± 0.98) | |
| Hoppe [66] (Comparative, Case control)§ | Germany | > 2 years | VNS + BMP (ASM) | 6.8 years (SD 2.1, range 2–13) | 20 | 39.8 (SD: 10.2) | 8 (40) | 25.7 (SD: 13.4) | 2.47 (SD: ± 0.77) | SPS: 8 (40%) CPS: 18 (90%) SGS: 10 (50%) | Mean: 68.4 (SD 206.3) per month | Seizure frequency, ASM use and tolerability, VNS tolerability HRQoL, ASM use, adverse events |
| | | | BMP (ASM) | | 20 | 39 (SD: 8.5) | 8 (40) | 21.0 (SD: 9.2) | 2.24 (SD: ± 0.44) | SPS: 7 (35%) CPD: 17 (85%) SPS: 12 (60%) | Mean 8.2 (SD 10.4) per month |
| Marrosu [65] (Comparative Prospective case control) | Italy | 1 year | VNS implant | 1 year | 10 | 33.1 (23–44) | 4 (40) | NR | 1.9 | CPS | Mean 156 (range: 98–212) per trimester | Seizure frequency, GRD distribution |
| | | | No implant | 7 | 30.8 (21–42) | 3 (43) | 1.9 | |

† Seizure types: SPS: Sensory Partial Seizures; CPS: Complex Partial Seizures; SGS: Simple Grand Mal Seizures. ‡ Percentage of patients with seizures of a specific type.
| Author / Publication | Location | Treatment length | Comparators | Sample size, n | Age at implant mean (SD [range]) | Sex, F (n [%]) | Mean duration of disease | Mean no. of ASMs used | Seizure types,† n (‡) | Seizure frequency | Outcomes Assessed |
|----------------------|----------|------------------|-------------|---------------|----------------------------------|----------------|--------------------------|------------------------|----------------------|------------------|-------------------|
| Boon [63] (Comparative Prospective Cohort) | Belgium | Average 26 months [range 12–57 months] | VNS + ASM | 29 months (range: 12–57) | 25 | 31 years (range: 12–49 years) | NR | 21 years (range: 2–50 years) | NR | SPS + SG: 15 (60%) | Mean: 21 per month (range: 2 to 180) | Epilepsy-related direct medical costs, Seizure frequency Number and dosage of ASMs, Number of hospital admission days clinic visits and laboratory tests |
| Surgery | 28 months (range, 12–54) | 35 | 32 (range: 10–60 years) | SPS + SG: 1 (3%) | Mean: 6 per month (range: 1 to 17) |
| ASM only | 25 (range: 12–48) | 24 | 34 years (range: 5–71 years) | CPS: 7 (29%) | Mean: 12 per month (range: 1 to 30) |
| Tatum [68] (Comparative Prospective case control) | US | 13.2 months | VNS | 13.2 months (NR) | 21 | 24.8 (range: 4–51) | 9 (43) | 17.0 (range: 4–45) | 2.81 (range: 1–5) | NR | NR | Seizure frequency, ASM dose and usage, QoL |
| Control (ASM) | 21 | 26.1 (5–57) | 12 (57) | 19.9 (range: 3–46) | 2.38 (range: 1–4) |
| Author / Publication          | Location | Treatment length | Comparators | Duration of Follow-up | Sample size, n | Age at implant mean (SD [range]) | Sex, F (n [%]) | Mean duration of disease | Mean no. of ASMs used | Seizure types,† n | Seizure frequency | Outcomes Assessed                                                                 |
|------------------------------|----------|------------------|-------------|-----------------------|----------------|---------------------------------|----------------|--------------------------|----------------------|------------------|-----------------|----------------------------------------------------------------------------|
| Harden [67]                  | US       | 3 months         | VNS         | 3 months (SD 1.7)     | 20             | 39 (SD: 9.1 [range: 20–58])     | 14 (70)        | NR                       | NR                   | CPS: 12 (60%) CP + secondarily GTC: 5 (25%) Primary GTC: 3 (15%) | Mean: 16.2 (SD 19.4) per month | Seizure frequency, Medication side effects, HRQoL |
|                             |          |                  | BMP (ASM)   | 3.8 months (SD 1.6)   | 20             | 40.2 (SD: 13.3 [range: 24–69])  | 14 (70)        |                           |                      | CPS: 10 (50%) Secondarily GTC: 5 (25%) CP + Secondarily GTC: 5 (25%) | Mean: 3.2 (SD 7.4) per month |                     |

Abbreviations: ASM anti-seizure medication, BMP best medical practice, CPS complex partial seizures, GABA_A gamma-aminobutyric acid, GRD GABA_A receptor density, GTC generalized tonic–clonic seizures, HRQoL health-related quality of life, NR not reported, psych psychogenic nonepileptic seizures, RCT randomised controlled trial, SD standard deviation, SG secondary generalisation, SPS simple partial seizures, SZ seizure, VNS vagus nerve stimulation

† May be counted in more than one type; ‡Where applicable; §Cyberonics-sponsored VNS study (Cyberonics is owned by LivaNova)
[95% CI 1.47, 3.51]; p = 0.0002). A similar statistically significant result was observed when results were pooled by study type (RCTs: OR 1.93 [95% CI 1.16, 3.20], p = 0.01; observational comparative studies: OR 3.64 [95% CI 1.51, 8.73], p = 0.004). Low levels of heterogeneity were observed between studies (Fig. 2).

**Participants experiencing ≥ 75% reduction in seizure frequency**

Five studies (two RCTs and three comparative observational studies) were included in the analysis. In the pooled analysis, the odds of experiencing ≥ 75% reduction in seizure frequency were more than three times greater in adult participants undergoing VNS Therapy compared with low-stimulation VNS Therapy/ASM (OR: 3.56 [95% CI 1.59, 7.98]; p = 0.002). A similar statistically significant result was observed for pooled RCT studies (OR 5.54 [95% CI 1.56, 19.67]; p = 0.008); pooled results for comparative observational studies were not statistically significant (OR: 2.43 [95% CI 0.83, 7.11]; p = 0.11). A trend for a greater VNS Therapy treatment effect in RCTs at a shorter follow-up time (OR 5.54 [95% CI 1.56, 19.67]) compared with observational data at a longer follow-up time (OR: 2.43 [95% CI 0.83, 7.11]) was observed. Low levels of heterogeneity were observed between studies (Fig. 3).

**Participants that are seizure free**

A total of six studies (two RCTs and four comparative observational studies) were included in the analysis. There is no difference in the odds of freedom from seizures in adult participants undergoing VNS Therapy compared with low-stimulation VNS Therapy/ASM (OR: 0.82 [95% CI 0.37, 1.84]; p = 0.64). On a study level, results were inconsistent across RCTs and comparative observational studies. Moderate levels of heterogeneity were observed between studies and there were large levels of uncertainty across the trial estimates due to low event numbers (Fig. 4).

**Mean change from baseline in seizure frequency**

Three RCT studies were included in the analysis. VNS Therapy was associated with a statistically significant decrease in the percentage change from baseline in seizures compared with low VNS Therapy (CFB: −18.26% [95% CI −20.12, −16.41]; p < 0.00001). Consistent results were observed across the three RCTs reporting on this outcome and low levels of heterogeneity were observed (Fig. 5).

**ASM load**

The analysis for ASM load was based on two studies (one RCTs and one comparative observational studies). In the pooled analysis, participants undergoing VNS Therapy had a significant reduction in the risk of having an increased ASM load when compared with BMP or control (case-matched participants on ASMs) (risk ratio [RR]: 0.36 [95% CI 0.21, 0.62]; p = 0.0002). Similarly, pooled analysis indicated that participants undergoing VNS Therapy had a significant reduction in the risk of adding one or more new ASMs during treatment when compared with BMP or control (case-matched participants on ASMs) (RR: 0.28 [95% CI 0.13, 0.58]; p = 0.0007). Results from a single RCT and comparative observational study formed the pooled analysis for both outcomes; low levels of heterogeneity were observed between studies. Separately, both studies reported significant differences for both outcomes favouring VNS Therapy (see Figs. 6 and 7).

**VNS Therapy discontinuation**

The discontinuation analysis included two RCT studies; no difference in the odds of discontinuing VNS Therapy treatment in adult participants undergoing VNS Therapy versus low-stimulation VNS Therapy/BMP was observed (OR: 1.31 [95% CI 0.51, 3.36]; p = 0.57). Consistent

---

**Table 3 Summary of high and low stimulation parameters**

| VNS therapy parameter | Landy 1993 | E-03 (Salinsky 1995) | E-05 (Handforth 1998) |
|-----------------------|-----------|---------------------|---------------------|
| Device setting        | Low       | High                | Low                 | High                |
| Output current (mA)   | 0.5–3.0   | 0.5–3.0             | 0.25–2.75           | 0.25–3.0            | 1.2 (avg) | 1.3 (avg) |
| Signal frequency (Hz) | 1–2       | 20–50               | 1–2                 | 20–50               | 1         | 30        |
| Pulse width (µsec)    | 130       | 500                 | 130                 | 500                 | 130       | 500       |
| Signal on time (sec)  | 30        | 30–90               | 30                  | 30–90               | 30        | 30        |
| Signal off time (min) | 60–180    | 5–10                | 60–180              | 5–10                | 180       | 5         |
Fig. 1 PRISMA flow diagram. Abbreviations: RCT randomised controlled trial, VNS, Vagus Nerve Stimulation. *Primarily due to publications including non-relevant comparators, no outcomes of interest or publications were superseded by a linked publication.
results were observed across the two RCTs reporting on this outcome. Low levels of heterogeneity were observed between studies and there were large levels of uncertainty across the trial estimates due to low event numbers (Fig. 8).

SAEs

A single RCT study was included in the SAE analysis. No difference in the odds of an SAE in adult participants undergoing VNS Therapy compared with BMP was observed (OR: 1.87 [95% CI 0.42, 8.24]; p = 0.41) (Fig. 9).

Discussion

This systematic review and meta-analysis demonstrated that in people with DRE, adjunctive high-stimulation VNS Therapy resulted in statistically significant reductions in seizure frequency without increasing the rate of SAEs or discontinuations when compared with adjunctive low-stimulation VNS Therapy/ASM/best medical practice. This evidence validates the consideration of VNS Therapy for people who respond poorly to ASMs, or those who are unsuitable for or unwilling to undergo any cranial procedure. Furthermore, the results of this study are in agreement with the current guideline recommendations for the use of VNS Therapy in adults [27, 70–72].

While VNS Therapy resulted in a statistically significant outcomes at the pooled level, some were not statistically significant at the trial level. For the ≥ 50% reduction in seizure frequency outcome, only a single trial was statistically significant at the trial level (E03). The other studies (E-05 and PuLsE) were not statistically significant likely due to the low number of participants involved and wide confidence intervals observed. For the ≥ 75% reduction in seizure frequency outcome, the pooled analysis (RCTs and comparative observational studies) and pooled RCT analysis both reported a statistically significant benefit of VNS Therapy. However, the pooled results for the comparative observational studies were not statistically significant, possibly due to study heterogeneity (specifically participant number, study length) and different magnitudes of treatment effects.

There is no difference in the odds of complete freedom from seizures for adult participants undergoing VNS Therapy versus low-stimulation VNS Therapy/ASM. This result reflects current evidence in the literature, with other studies reporting that people with DRE undergoing VNS Therapy have a low rate of seizure freedom, despite response and seizure freedom rates increasing over time [73]. It must be noted that no events for seizure freedom were observed in RCT studies included in this analysis, with seizure freedom events only recorded in the comparative observational studies, which have a longer follow-up. Seizure freedom, however, was observed in 15 of 273 individuals with DRE.

The beneficial impact of VNS Therapy on ASM load was limited to two studies (PuLsE RCT and Tatum 2001), indicating that participants are less likely to require new ASMs or have an increased ASM load compared with BMP or control (case-matched participants on ASMs). When viewed alongside other seizure control outcomes from this analysis, the evidence suggests that VNS Therapy may permit
the reduction in concomitant ASMs without loss of seizure control. A lower drug burden is clinically important, because excessive drug load may be associated with decreased tolerability, and may consequently reduce the likelihood of seizure freedom [74]. Furthermore, certain ASMs are linked with a range of metabolic consequences that can adversely affect bone, lipid, and gonadal steroid metabolism. Consequently, reducing the drug burden may lower the risk of such complications [75]. Reductions in ASM load may also improve participant QoL, as a greater number of ASMs is a significant predictor of poor QoL [76]. In addition, studies have shown that seizure frequency in people with DRE was one of the most important factors contributing to patient QoL [77, 78]. Consequently, a reduction in seizures and their frequency may translate into QoL benefits. Of note, several studies which investigated use of VNS Therapy in individuals with DRE report improvements in seizure control and also observed improvements in QoL [35, 67, 79].

VNS therapy has comparable safety outcomes, specifically for SAEs and discontinuations, when compared with

---

### Table 1: Reductions in ASM Load

| Study or Subgroup | VNS Events | Control Events | Odds Ratio | Odds Ratio |
|-------------------|------------|----------------|------------|------------|
|                   | Total      | Total          | M-H, Fixed, 95% CI | M-H, Fixed, 95% CI |
| **6.1 RCTs (adults)** |            |                |             |             |
| E03 (3.5 months) [RCT: High VNS vs low VNS] | 4 | 54 | 160 | 12.3% | 4.72 [0.51, 43.61] | 4.72 [0.51, 43.61] |
| E05 (3.4-4.5 months) [RCT: High VNS vs low VNS] | 10 | 94 | 102 | 24.1% | 5.95 [0.27, 27.92] | 5.95 [0.27, 27.92] |
| Subtotal (95% CI) | 148 | 162 | 36.4% | 5.54 [1.56, 19.67] | 5.54 [1.56, 19.67] |
| Total events | 14 | 3 |             |             |             |
| Heterogeneity: $\chi^2 = 0.03$, df = 1 (P = 0.87), $\nu = 0$% | | | Test for overall effect: Z = 2.64 (P = 0.008) | |

### Fig. 3: Participants experiencing ≥ 75% reduction in seizure frequency.

Abbreviations: ASM antiepileptic drug, CI confidence interval, RCT randomised controlled trial, SD standard deviations, VNS vagus nerve stimulation

### Fig. 4: Seizure-free participants.

Abbreviations: ASM antiepileptic drug, CI confidence interval, RCT randomised controlled trial, SD standard deviation, VNS Vagus Nerve Stimulation
low-stimulation VNS Therapy/best medical practice. There was no difference in the odds of discontinuing treatment in adult participants undergoing VNS Therapy versus low-stimulation VNS Therapy/best medical practice, and there was no difference in the odds of an SAE in adult participants undergoing VNS Therapy versus best medical practice. When viewed alongside the seizure control outcomes from this analysis, the safety evidence suggests that VNS Therapy may facilitate better seizure control without increasing the rate of discontinuation or SAEs compared with participants undergoing VNS Therapy versus low-stimulation VNS Therapy/best medical practice. The discontinuation analysis was based on two RCTs of different duration; 12 months (PuLsE) and 3.4–4.5 months (E-05). Of note, there was only a single event in the VNS Therapy and comparator arm for E-05 compared with 46 and 47 events in the VNS Therapy and comparator arm for PuLsE. The main reasons for discontinuation in E-05 were Cheyne–Stokes respiration ($n=1$), and a variety of unspecified symptoms ($n=1$). For PuLsE, the majority of study discontinuations in either treatment group were due to premature termination of the study by the sponsor, and there were no discontinuations due to AEs.

It must be noted that of the studies identified for the meta-analysis, there was only one RCT (PuLsE; which had its outcomes restricted to 12 months for the meta-analysis) [35] and two comparative observational studies [63, 64] which reported long-term outcomes (≥ 2 years). Consequently, this makes it difficult to determine the long-term benefits associated with VNS Therapy. However, there are non-comparative, single-arm studies of VNS Therapy in people with DRE which provide an insight into the long-term treatment effects of VNS Therapy. A retrospective analysis of 436 participants (predominantly adults) with DRE treated with
VNS Therapy reported that participants achieved a mean seizure reduction of 55.8% after a mean follow-up of 5 years; 40.5 and 63.75% of participants achieved ≥ 75% seizure control and ≥ 50% seizure control, respectively [80]. The mean reduction in seizures continued to improve with duration; of those participants with > 10 years of follow-up (n = 65), the mean decrease in seizure frequency at last follow-up was 76.3% [81]. In addition, results from a prospective, open-label study of long-term VNS Therapy use (2 years) in individuals with DRE (n = 40) reported no significant safety events associated with Therapy and 95% (38/40) of patients remained on VNS Therapy for the study duration (one patient died [SUDEP] and the other was lost to follow-up after 1 year of treatment) [82]. The long-term benefits of VNS Therapy are reported in a number of other single-arm studies [83–85]. These results highlight the long-term benefits of VNS Therapy for people with DRE, but long-term comparative studies are required to determine if the benefits observed were solely due to VNS Therapy, or a potentially synergistic combination of ASM regimens and VNS Therapy. There are single-arm studies of shorter duration which support the meta-analysis results for VNS Therapy and ASM load. DeGiorgio et al. 2000 reported that participants with refractory epilepsy (n = 195) who were treated with VNS Therapy had a reduction in the mean number of ASMs, from 2.3 to 2.1 at the end of 12 months [46]. In addition, another study reported that up to 40% of participants experienced a decrease in the total dose of ASMs after 12 months of VNS Therapy [86]. While positive, these observations need to be supported by long-term comparative studies.
As with all systematic reviews and meta-analyses, the results may need to be interpreted with caution due to certain limitations which include inconsistency across the trials for length of follow-up, greater treatment effects were often observed with observational comparative studies versus RCTs, and there were a very limited number of studies (≤ 2) for certain meta-analysis outcomes, specifically the discontinuation, SAE, and ASM load analyses. Of note, the number of studies identified for the meta-analysis was limited as the analysis focused on comparative observational studies and RCTs (which are the gold standard for generating estimates of relative treatment effects) which can be viewed as a strength of this analysis. Overall, there is limited high-quality evidence supporting the use of VNS Therapy in DRE. In addition, many trial-level estimates are associated with large levels of uncertainty (wide CIs) due to low participant and event numbers and in some instances single events are driving the direction of treatment effects. There was substantial variation in baseline seizure frequency reported by observational comparative studies (0.1–3.5 seizures per day). Seizure frequency in VNS Therapy participants and control participants were not comparable at baseline in the majority of reporting studies, with participants in the VNS Therapy arm having a greater baseline seizure frequency [63, 66, 67]. Another limitation of the analysis was the differences in VNS Therapy stimulation parameters across studies contributing to further heterogeneity amongst participant groups. In the early RCTs regulating stimulation parameters, the low-stimulation group was titrated to sensation and the high stimulation group to maximum tolerated stimulation. Subsequent studies have suggested this may not be necessary for optimal efficacy and may contribute to difficulties in tolerability. Finally, three of the VNS Therapy trials informing efficacy (E-03, E-05 and Landy 1993) did not compare VNS Therapy with ASM therapy only. These trials compared VNS Therapy at ‘high stimulation’ settings with a presumed sub-therapeutic ‘low-stimulation’ regimen; ASMs were given in both arms. Therapeutic VNS is driven by the generation of action potentials along the vagus nerve, which is a function of the strength-duration relationship [87]. It is reported in the literature that 1.5 mA at 130 µsec to 2.25 mA at 500 µsec is considered a therapeutic dose [20, 62, 69, 88]. Based on the reported data, the low-stimulation arms in each of these trials contain patients that could fall within this therapeutic range (see Table 3). Consequently, any residual benefit of ‘low-stimulation’ may have resulted in the overestimation of the efficacy of ASMs in the low-stimulation group.

This study has highlighted areas of focus for future research. There is a need for comparative studies assessing the long-term efficacy and safety of VNS Therapy as an adjunct to ASMs compared with relevant comparators. In addition, more research is required to reinforce the positive results observed for ASM load when VNS Therapy is used as an adjunct to ASMs.

**Conclusions**

Although there is much literature devoted to VNS Therapy, there is a paucity of comparative data and this should be a focus for future research. This meta-analysis demonstrated the benefits of VNS Therapy in people with DRE, which included improvement in seizure frequency without an increase in the rate of SAEs or discontinuations. The evidence validates the consideration of VNS Therapy for people...
who are not responding to ASMs, or those who are unsuitable for or unwilling to undergo cranial procedures.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00415-022-10967-6.

Acknowledgements Christa Zachariah and Shauna Garris, Medical Science Liaison Managers at LivaNova for their contribution to the tabulation of the data. Writing support was provided by Éanna Connaughton (Mtech Access).

Author contributions FB, JM and VD conceptualised the project. SB and SM planned and conducted the investigation and the formal analysis. All authors were involved in the writing, review and editing of the manuscript.

Funding This study was funded by LivaNova.

Declarations

Conflicts of interest Rohit Shankar has received institutional and research support from LivaNova, UCB, Eisai, Veriton Pharma, Bial, Averelle and GW pharmaceuticals outside the submitted work. He was the author/lead of the Royal College of Psychiatrists reports CR203, CR206 and the National Step Together Report. He is also the medical lead of the freely available SUDEP and Seizure safety Checklist and EpsSMon App. He is the developmental disabilities representative in the recent NICE revision/update of the epilepsies (2022), the NHS RightCare report (2020), the NHS England specialist commissioning report for epilepsy (2021) and the National Confidential Inquiry into epilepsy deaths (2021–22). Joan Conry has received research funding from LivaNova. Jane Boggs has received research funding from LivaNova, Medtronic and UCB. Francesca Barion, Joanna Murphy and Vanessa Danielson are employees of LivaNova. Sarah Batson, Stephen Mitchell and Rodney Radtke have no competing interests to declare that are relevant to the content of this article.

Ethical standards The manuscript does not contain clinical studies or patient data.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. World Health Organization (WHO) (2019) Epilepsy Overview. Available from: https://www.who.int/health-topics/epilepsy. Accessed on: 16th July 2021

2. Kalilani L, Sun X, Pelgroms B, Noack-Rink M, Villanueva V (2018) The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia 59(12):2179–2193. https://doi.org/10.1111/epi.14596

3. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G et al (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 51(6):1069–1077. https://doi.org/10.1111/j.1528-1167.2009.02397.x

4. Strzelczyk A, Griebel C, Lux W, Rosenow F, Reese J-P (2017) The burden of severely drug-refractory epilepsy: a comparative longitudinal evaluation of mortality, morbidity, resource use, and cost using german health insurance data. Front Neurol. https://doi.org/10.3389/fneur.2017.00712

5. Kantanen AM, Reimkainen M, Parviainen I, Kälviäinen R (2017) Long-term outcome of refractory status epilepticus in adults: a retrospective population-based study. Epilepsy Res. https://doi.org/10.1016/j.eplepsyres.2017.03.009

6. Wang T, Wang J, Dou Y, Yan W, Ding D, Lu G et al (2020) Clinical characteristics and prognosis in a large paediatric cohort with status epilepticus. Seizure 80:5–11. https://doi.org/10.1016/j.seizure.2020.04.001

7. Tian L, Li Y, Xue X, Wu M, Liu F, Hao X et al (2015) Super-refractory status epilepticus in West China. Acta Neurol Scand 132(1):1–6. https://doi.org/10.1111/ane.12336

8. Novak JL, Miller PR, Markovic D, Meymandi SK, DeGiorgio CM (2015) Risk assessment for sudden death in epilepsy: The Sudep-7 inventory. Front Neurol 6:252. https://doi.org/10.3389/fneur.2015.00252

9. Ryvlin P, Cucherat M, Rheims S (2011) Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol 10(11):961–968. https://doi.org/10.1016/S1474-4422(11)70193-4

10. Devinsky O, Hesdorffer DC, Thurman DJ, Lhatoo S, Richerson W, Mathern G et al (2010) Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia 51(6):1069–1077. https://doi.org/10.1111/j.1528-1167.2009.02397.x

11. Ridsdale L, Wojewodka G, Robinson E, Landau S, Noble A, Taylor S et al (2017) Characteristics associated with quality of life among people with drug-resistant epilepsy. J Neurol 264(6):1174–1184. https://doi.org/10.1007/s00415-017-8512-1

12. Brodie MJ (2013) Road to refractory epilepsy: the Glasgow story. Epilepsia 54(Suppl 2):5–8. https://doi.org/10.1111/epi.12175

13. Chen Z, Brodie MJ, Liew D, Kwan P (2018) Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol 75(3):279–286. https://doi.org/10.1001/jamaneurol.2017.3949

14. Epilepsy Action (2020) Epilepsy brain surgery for adults. Available from: https://www.epilepsy.org.uk/info/treatment/surgery/adult#brain1 Accessed on: 16th July 2021

15. Masino SA, Rho JM (2012) Mechanisms of Ketogenic Diet Action. In: Noebels JL, Avoli M, Rogawski MA, al. e, editors. Jasper’s Basic Mechanisms of the Epilepsies, 4th edition. Bethesda (MD): National Center for Biotechnology Information (US)

16. Zangiabadi N, Ladino LD, Sina F, Orozco-Hernández JP, Carter A, Téllez-Zenteno JF (2019) Deep brain stimulation and drug-resistant epilepsy: a review of the literature. Front Neurol 10:601. https://doi.org/10.3389/fneur.2019.00601

17. Epilepsy Foundation (2017) Responsive Neurostimulation (RNS). Available from: https://www.epilepsy.com/learn/treating-seizures-and-epilepsy/devices/responsive-neurostimulation-rns. Accessed on: 16th July 2021

18. Ben-Menachem E, Revesz D, Simon BJ, Silverstein S (2015) Surgically implanted and non-invasive vagus nerve
19. PR Newswire (2012) NeuroSigma receives CE certification. Available from: https://www.prnewswire.com/news-releases/neurosigma-receives-ce-certification-168578146.html. Accessed on: 21 July 2021

20. Handforth A, DeGiorgio CM, Schachter SC, Uthman BM, Naritoku DK, Tecomà ES et al (1998) Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 51(1):48–55. https://doi.org/10.1212/wnl.51.1.48

21. The Vagus Nerve Stimulation Study Group (1995) A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology 45(2):224–230. https://doi.org/10.1212/wnl.45.2.224

22. Sheng J, Liu S, Qin H, Li B, Zhang X (2018) Drug-resistant epilepsy and surgery. Curr Neuropharmacol 16(1):17–28. https://doi.org/10.2174/1570159115666170504123316

23. de Tisi J, Bell GS, Peacock JL, McEvoy AW, Harkness WF, Sander JW et al (2011) The long-term outcome of adult epilepsy surgery, patterns of seizure remission, and relapse: a cohort study. Lancet (London, England) 378(9780):1388–1395. https://doi.org/10.1016/s0140-6736(11)60890-8

24. Ryvlin P, Rheims S (2008) Epilepsy surgery: eligibility criteria and presurgical evaluation. Dialogues Clin Neurosci 10(1):91–103

25. Liu G, Slater N, Perkins A (2017) Epilepsy: treatment options. Am Fam Phys 96(2):87–96

26. Englot DJ, Birk H, Chang EF (2017) Seizure outcomes in non-refractory epilepsy surgery: an update. Neurosurg Rev 40(2):181–194. https://doi.org/10.1007/s10143-016-0725-8

27. NHS Commissioning Board (2013) Clinical Commissioning Policy: Vagal Nerve Stimulation for Epilepsy. 01 August 2021

28. LivaNova VNS Therapy® System Epilepsy Physician’s Manual. August 2020. OUS version

29. LivaNova VNS Therapy® System Epilepsy Physician’s Manual. May 2020. US version

30. LivaNova Data on file (Certification Notice CE Marking [KCS/MD - 37600] May 1, 1994

31. Food and drug administration (FDA) (1997) Premarket Approval (PMA) P970003. VNS THERAPY SYSTEM. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpm/ pma.cfm?id=P970003 Accessed on: 21 July 2021

32. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol 134:178–189. https://doi.org/10.1016/j.jclinepi.2021.03.001

33. National Institute for Health and Care Excellence (NICE) (2015) Single technology appraisal: User guide for company evidence submission template (PMG24). Available from: https://www.nice.org.uk/process/pmg24/resources/single-technology-appraisal-user-guide-for-company-evidence-submission-template-pdf-7228671541933 Accessed on: 01 July 2021

34. Effective Public Health Practice Project (EPHPP) (2021) Quality Assessment Tool for Quantitative Studies. Available from: https://www.ephpp.ca/quality-assessment-tool-for-quantitative-studies/. Accessed on: 01 July 2021

35. Ryvlin P, Gilliam FG, Nguyen DK, Colicchio G, Judice A, Tinuper P et al (2014) The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PulsE (Open Prospective Randomized Long-term Effectiveness) trial. Epilepsia 55(6):893–900. https://doi.org/10.1111/epi.12611

36. Ben-Menachem E, Mañón-Espaillat R, Ristanovic R, Wilder BJ, Stefan H, Mirza W et al (1994) Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First International Vagus Nerve Stimulation Study Group. Epilepsia 35(3):616–626. https://doi.org/10.1111/j.1528-1157.1994.tb02482.x

37. Ramsay RE, Uthman BM, Augustinsson LE, Upton AR, Naritoku D, Willis J et al (1994) Vagus nerve stimulation for treatment of partial seizures: 2. Safety, side effects, and tolerability. First International Vagus Nerve Stimulation Study Group. Epilepsia 35(3):627–636. https://doi.org/10.1111/j.1528-1157.1994.tb02483.x

38. Holder LK, Wernicke JF, Tarver WB (1992) Treatment of refractory partial seizures: preliminary results of a controlled study. Pacin Clin Electrophysiol PACE 15(10 Pt 2):1557–1571. https://doi.org/10.1111/j.1540-8159.1992.tb02934.x

39. Morris GL 3rd (2003) A retrospective analysis of the effects of magnet-activated stimulation in conjunction with vagus nerve stimulation therapy. Epilepsy Behav E&B 4(6):740–745. https://doi.org/10.1016/j.yebeh.2003.08.025

40. Michael JE, Wegener K, Barnes DW (1993) Vagus nerve stimulation for intractable seizures: one year follow-up. J Neurosci Nurs 25(6):362–366. https://doi.org/10.1097/01736517-199310000-00007

41. George R, Salinsky M, Kuzniecky R, Rosenfeld W, Bergen D, Tarver WB et al (1994) Vagus nerve stimulation for treatment of partial seizures: 3. Long-term follow-up on first 67 patients exiting a controlled study. First International Vagus Nerve Stimulation Study Group. Epilepsia 35(3):637–643. https://doi.org/10.1111/j.1528-1157.1994.tb02484.x

42. Holder LK, Wernicke J, Tarver WB (1993) Long-term follow-up of 37 patients with refractory partial seizures treated with vagus nerve stimulation. J Epilepsy 6(4):206–214

43. Amar AP, Heck CN, Levy ML, Smith T, DeGiorgio CM, Oviedo S et al (1998) An institutional experience with cervical vagus nerve trunk stimulation for medically refractory epilepsy: rationale, technique, and outcome. Neurosurgery 43(6):1265–76; https://doi.org/10.1097/00006123-199812000-00001

44. Dodrill CB, Morris GL (2001) Effects of vagal nerve stimulation on cognition and quality of life in epilepsy. Epilepsy Behav E&B 2(1):46–53. https://doi.org/10.1016/1528-1157.2000.0148

45. Amar AP, DeGiorgio CM, Tarver WB, Apuzzo ML (1999) Long-term multicenter experience with vagus nerve stimulation for intractable partial seizures: results of the XE5 trial. Stereotact Funct Neurosurg 73(1–4):104–108. https://doi.org/10.1111/j.1528-1157.1999.tb00764.x

46. DeGiorgio CM, Schachter SC, Handforth A, Salinsky M, Thompson J, Uthman B et al (2000) Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia 41(9):1195–1200. https://doi.org/10.1111/j.1528-1157.2000.tb00325.x

47. DeGiorgio CM, Thompson J, Lewis P, Arrambide S, Naritoku D, Handforth A et al (2001) Vagus nerve stimulation: analysis of device parameters in 154 patients during the long-term XE5 study. Epilepsia 42(8):1017–1020. https://doi.org/10.1046/j.1528-1157.2001.0420081017.x

48. Bunch S, DeGiorgio CM, Krahli S, Britton J, Green P, Lancman M et al (2007) Vagus nerve stimulation for epilepsy: is output current correlated with acute response? Acta Neurol Scand 116(4):217–220. https://doi.org/10.1111/j.1600-0404.2007.00878.x

49. DeGiorgio C, Heck C, Bunch S, Britton J, Green P, Lancman M et al (2005) Vagus nerve stimulation for epilepsy: randomized comparison of three stimulation paradigms. Neurology 65(2):317–319. https://doi.org/10.1212/01.wnl.0000168899.11598.00

50. Wang AJ, Bick SK, Williams ZM (2020) Vagus nerve stimulation versus responsive neurostimulator system in patients with temporal lobe epilepsy. Stereotact Funct Neurosurg 98(1):21–29. https://doi.org/10.1115/000504859
51. Bhragavansh A (2020) VNS and RNS patients are driving: The impact of seizure freedom and reduction American Epilepsy Society. Abstract 154

52. Ellens NR, Elisevich K, Burdette DE, Patra SE (2018) A comparison of vagal nerve stimulation and responsive neurostimulation for the treatment of medically refractory complex partial epilepsy. Stereotact Funct Neurosurg 96(4):259–263. https://doi.org/10.1159/000492232

53. Kuba R, Novák Z, Chrastina J, Pažourková M, Hermanová M, Ošlejšková H et al (2013) Comparing the effects of cortical resection and vagus nerve stimulation in patients with nonlesional extratemporal epilepsy. Epilepsy Behav E&B 28(3):474–480. https://doi.org/10.1016/j.yebeh.2013.05.036

54. Wheless JW, Isojarvi J, Lee D, Drummond R, Benbadis SR (2014) Clonazepam is efficacious for patients across the spectrum of disease severity of Lennox-Gastaut syndrome: post hoc analyses of clinical trial results by baseline seizure-frequency quartiles and VNS experience. Epilepsy Behav E&B 41:47–52. https://doi.org/10.1016/j.yebeh.2014.09.019

55. Nei M, O’Connor M, Liporace J, Sperling MR (2006) Refractory seizure frequency quartiles and VNS experience. Epilepsy Behav E&B 41:47–52. https://doi.org/10.1016/j.yebeh.2014.09.019

56. McClone J, Valdivia I, Penner M, Williams J, Sadler RM, Clarke DB (2008) Quality of life and memory after vagus nerve stimulator implantation for epilepsy. Canadian J Neurol Sci J Canadien des Sci Neurol 35(2):287–296. https://doi.org/10.1017/s031716710008854

57. Lim Z, Wong K, Downs J, Bebbington K, Demarest S, Leonard H (2018) Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder. Epilepsy Res 146:36–40. https://doi.org/10.1016/j.eplepsyres.2017.07.013

58. Ben-Menachem E, Hamberger A, Hedner T, Hammond EJ, Uhman BM, Slater J et al (1995) Effects of vagus nerve stimulation on amino acids and other metabolites in the CSF of patients with partial seizures. Epilepsy Res 20(3):221–227. https://doi.org/10.1016/0920-1211(94)00083-9

59. Drees CS, McDermott D, Abosch D, Ojemann A, Brown MG (2018) Responsive neurostimulation (RNS) use in patients with and without prior vagus nerve stimulator (VNS) implantation. Am Epilepsy Soc Abst 1:165

60. Jamy R, Kaur M, Pizarro D, Toth E, Pati S (2019) Practice trends and the outcome of neuromodulation therapies in epilepsy: A single-center study. Epilepsia open 4(3):493–497. https://doi.org/10.1002/epio.12345

61. Boon P, Vandekerckhove T, Achten E, Thiery E, Goossens L, Vonck K et al (1999) Efficacy of vagus nerve stimulation for the treatment of refractory epilepsy: a comparison of vagal nerve stimulation and responsive neurostimulation in patients with nonlesional extratemporal epilepsy. Epilepsia 40(5):561–563. https://doi.org/10.1016/wul.56.4.561

62. Landy HJ, Ramsay RE, Slater J, Casiano RR, Morgan R (1993) Vagus nerve stimulation for complex partial seizures: surgical experience. Epilepsia 47(1):115–122. https://doi.org/10.1016/S0920-1211(03)00107-4

63. Gonen OM, Gandelman-Marton R, Kipervasser S, Neufeld MY (2010) Antiepileptic drugs and quality of life in people with epilepsy. Seizure 16(2):128–133. https://doi.org/10.1016/j.seizure.2009.11.003

64. Lim Z, Wong K, Downs J, Bebbington K, Demarest S, Leonard H (2018) Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder. Epilepsy Res 146:36–40. https://doi.org/10.1016/j.eplepsyres.2017.07.013

65. Marrosu F, Serra A, Maleci A, Puligheddu M, Biggio G, Piga M (2003) Correlation between GABA(A) receptor density and vagus nerve stimulation in individuals with drug-resistant partial epilepsy. Epilepsy Res 55(1–2):59–70. https://doi.org/10.1016/s0920-1211(03)00107-4

66. Hoppe C, Wagner L, Hoffmann JM, von Lehe M, Elger CE (2013) Comprehensive long-term outcome of best drug treatment with or without add-on vagus nerve stimulation for epilepsy: a retrospective matched pairs case-control study. Seizure 22(2):109–115. https://doi.org/10.1016/j.seizure.2012.11.003

67. Harden CL, Pulver MC, Radvin LD, Nikolov B, Halper JP, Labar DR (2000) A pilot study of mood in epilepsy patients treated with vagus nerve stimulation. Epilepsy & behavior : E&B 1(1):93–99. https://doi.org/10.1006/y.ebeh.2000.0046

68. Tatum WO, Johnson KD, Goff S, Ferreira JA, Vale FL (2001) Vagus nerve stimulation and drug reduction. Neurology 56(4):561–563. https://doi.org/10.1212/wul.56.4.561

69. Salinsky MC, Uthman BM, Ristanovic RK, Wernicke JF, Tarver WB (1996) Vagus nerve stimulation for the treatment of medically intractable seizures. Results of a 1-year open-extension trial. Vagus Nerve Stimulation Study Group. Arch Neurol 53(11):1176–1180. https://doi.org/10.1001/archneur.1996.00550110128021

70. Morris GL, Gloss D, Buchhalter J, Mack KJ, Nickels K, Harden C (2013) Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 81(16):1453–1459

71. Deutsche Gesellschaft für Neurologie (DGN) (2017) Erster epileptischer Anfall und Epilepsien im Erwachsenenalter. Available from: https://www.awmf.org/uploads/tx_szeitleitlinien/030-0411_S1_Erster-epileptischer-Anfall_Epilepsien_2018-05.pdf. Accessed on: 01 August 2021

72. Calabria C, l’Epilessia (LICE)/Società Italiana di Medicina Generale (SIMG) Guida pratica per la gestione del paziente affetto da epilessia. Available from: https://www.lice.it/LICE_it/ LICE_it/ documenti/LICE-SIMG/pdf/1_clinica.pdf. Accessed on: 01 August 2021

73. Englot DJ, Chang EF, Auguste KI (2011) Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg 115(6):1248–1255. https://doi.org/10.3171/ 2011.7.Jns11977

74. Brodie MJ, Sills GJ (2011) Combining antiepileptic drugs—rational polytherapy? Seizure 20(5):369–375. https://doi.org/10.1016/j.seizure.2011.01.004

75. Mintzer S (2010) Metabolic consequences of antiepileptic drugs. Curr Opin Neurol 23(2):164–169. https://doi.org/10.1097/WCO. 0b013e32833735e7

76. George J, Kulkarni C, Sarma GRK (2015) Antiepileptic drugs and quality of life in patients with epilepsy: a tertiary care hospital-based study. Value Health Regional Issues 6:1–6. https://doi.org/10.1016/j.vhri.2014.07.009

77. Guekht AB, Mitrokhina TV, Lebedeva AV, Dzugaeva FK, Milchakova LE, Lokshina OB et al (2007) Factors influencing on quality of life in people with epilepsy. Seizure 16(2):128–133. https://doi.org/10.1016/j.seizure.2006.10.011

78. Kalitesi İDEHY (2019) Quality of life in patients with drug resistant epilepsy. Turk J Neurol 25:159–163

79. Kawai K, Tanaka T, Baba H, Bunker M, Ikeda A, Inoue Y et al (2011) Efficacy of vagus nerve stimulation over time: a prospective matched pairs case-control study. Seizure 22(2):109–115. https://doi.org/10.1016/j.seizure.2012.11.003

80. Elliott RE, Morsi A, Kalhorn SP, Marcus J, Sellin J, Kang M et al (2011) Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: long-term outcomes and predictors of response. Epilepsy Behav E&B 20(1):57–63. https://doi.org/10.1016/j.y.ebeh.2010.10.017

81. Elliott RE, Morsi A, Tanweer O, Grobelny B, Geller E, Carlson C et al (2011) Efficacy of vagus nerve stimulation over time: review of 65 consecutive patients with treatment-resistant epilepsy
treated with VNS > 10 years. Epilepsy Behav E&B 20(3):478–483. https://doi.org/10.1016/j.yebeh.2010.12.042

82. Huf RL, Mamela A, Kneedy-Cayem K (2005) Vagus nerve stimulation therapy: 2-year prospective open-label study of 40 subjects with refractory epilepsy and low IQ who are living in long-term care facilities. Epilepsy Behav E&B 6(3):417–423. https://doi.org/10.1016/j.yebeh.2005.01.009

83. Abubakr A, Wambacq I (2008) Long-term outcome of vagus nerve stimulation therapy in patients with refractory epilepsy. J Clin Neurosc 15(2):127–129. https://doi.org/10.1016/j.jocn.2007.07.083

84. Kuba R, Brázdil M, Kalina M, Procházka T, Hovorka J, Nezádal T et al (2009) Vagus nerve stimulation: longitudinal follow-up of patients treated for 5 years. Seizure 18(4):269–274. https://doi.org/10.1016/j.seizure.2008.10.012

85. Nakken KO, Henriksen O, Røste GK, Lossius R (2003) Vagal nerve stimulation—the Norwegian experience. Seizure 12(1):37–41. https://doi.org/10.1016/s1059131102001383

86. McLachlan RS, Sadler M, Pillay N, Guberman A, Jones M, Wiebe S et al (2003) Quality of life after vagus nerve stimulation for intractable epilepsy: is seizure control the only contributing factor? Eur Neurol 50(1):16–19. https://doi.org/10.1159/000070853

87. Geddes LA, Bourland JD (1985) The strength-duration curve. IEEE Trans Biomed Eng 32(6):458–459. https://doi.org/10.1109/tbme.1985.325456

88. Fisher B, DesMarteau JA, Koontz EH, Wilks SJ, Melamed SE (2020) Responsive Vagus Nerve Stimulation for Drug Resistant Epilepsy: A Review of New Features and Practical Guidance for Advanced Practice Providers. Frontiers in neurology 11:610379. https://doi.org/10.3389/fneur.2020.610379